GvHD prophylaxis with calcineurin or mTOR inhibitors were stopped in all patients within 2 weeks after diagnosis considering GvHD risk and the time point after administering HSCT with or without replacement therapy (mycophenolate-mofetil) (8, 9, 23, 54, 56, 57). This evidence concerns the gene MTOR and graft versus host disease.